Engineered growth factors and cutaneous wound healing: Success and possible questions in the past 10 years

Wound Repair and Regeneration

Volumn 13, Issue 2, 2005, Pages 122-130

  Fu, Xiaobing ^a   Li, Xiaokun ^b   Cheng, Biao ^a   Chen, Wei ^a   Sheng, Zhiyong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; RECOMBINANT GROWTH FACTOR; RECOMBINANT PLATELET DERIVED GROWTH FACTOR; SULFADIAZINE SILVER;

ACUTE DISEASE; BURN; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXPERIENCE; HUMAN; PRIORITY JOURNAL; REVIEW; SKIN INJURY; SKIN ULCER; TREATMENT FAILURE; WOUND HEALING;

DRUG DELIVERY SYSTEMS; GROWTH SUBSTANCES; HUMANS; PROFESSIONAL PRACTICE; RECOMBINANT PROTEINS; SKIN; TIME FACTORS; WOUND HEALING;

EID: 16844362298     PISSN: 10671927     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1067-1927.2005.130202.x     Document Type: Review

References (54)

1. Brown GL, Nanney LB, Griffen J, Gramer AB, Yancey JM, Curtsinger LJ, Holtzin L, Schultz GS, Jurkiewicz MJ, Lynch JB. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989;321:76-9.
2. Fu X, Shen Z, Chen Y, Xie J, Guo Z, Zhang M, Sheng Z. Randomized placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns. Lancet 1998;352:1661-4.
3. Fu X, Wang Z, Sheng Z. Advances in wound healing research in China: from antiquity to the present. Wound Rep Reg 2001;9:2-10.
4. Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing formula (PDWHF). Ann Surg 1986;204:322-30.
5. Knighton DR, Ciresi KF, Fiegel VD, Schumerth S, Butler E, Cerra F. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using autologous platelet-derived wound healing formula, Surg Gyn Obstet 1990;170:56-60,
6. Mustoe TA, Cutler NR, Allman RM, Goode PS, Deuel TF, Prause JA, Bear M, Derdar CM, Pierce GF. Phase II study to evaluate recombinant PDGF-BB in the treatment of pressure sores. Arch Surg 1994;129:21S-9.
7. Robson MC, Phillips LG, Lawrence WT, Bishop JB, Youngerman JS, Hayward PG, Broemeling LD, Heggers JP. The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 1992;216:401-6; discussion 406-8.
8. Fu X, Shen Z, Guo Z, Zhang M, Sheng Z. Healing of chronic cutaneous wounds by topical treatment with basic fibroblast growth factor. Chin Med J (Engl) 2002;115:331-5.
9. Fu X, Shen Z, Chen Y, Xie J, Guo Z, Zhang M, Sheng Z. Recombinant bovine basic fibroblast growth factor accelerates wound healing in patients with burns, donor sites and chronic dermal ulcers. Chin Med J (Engl) 2000;113:367-71.
10. Fu X, Cuevas P, Gimenez-Gallego G, Tian H, Sheng Z. Ischemia and reperfusion reduces the endogenous basic fibroblast growth factor in rat skeletal muscles. Chin Med J (Engl) 1995;108:699-703.
11. Fu X, Yang Y, Li X, Sun T, Wang Y, Sheng Z. Ischemia and reperfusion impair the gene expression of endogenous basic fibroblast growth factor in rat skeletal muscles. J Surg Res 1998;80:88-93.
12. Bennett NF, Schultz GS. Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am J Surg 1993;166:74-81.
13. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Rep Reg 2000;8:13-25.
14. Tarnuzzer RW, Schultz GS. Biochemical analysis of acute and chronic wound environments. Wound Rep Reg 1996;4:321-5.
15. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F, Murphy G, Schultz G. Analysis of the acute and chronic wound environments, the role of proteases and their inhibitors. Wound Rep Reg 1999;7:442-52.
16. Landau Z, David M, Aviezer D, Yayon A. Heparin-like inhibitory activity to fibroblast growth factor-2 in wound fluid of patients with chronic skin ulcers and its modulation during wound healing. Wound Rep Reg 2001;9:323-8.
17. Robson MC. Exogenous growth factor application effect on human wound healing. Prog Dermatol 1996;30:1-7.
18. Grazul-Bilska AT, Luthra G, Reynolds LP, Bilski JJ, Johnson ML, Adbullah SA, Redmer DA, Abdullah KM. Effects of basic fibroblast growth factor (FGF-2) on proliferation of human skin fibroblasts in type II diabetes mellitus. Exp Clin Endocrinol Diabetes 2002;110:176-81.
19. Cohen IK, Crossland MC, Garrett A, Diegelmann RF. Topical application of epidermal growth factor onto partial-thickness wounds in human volunteers does not enhance reepithelialization. Plast Reconstr Surg 1995;96:251-4.
20. Feng JWH, Wang J. Clinical study of various growth factors on the improvement of impaired healing ulcers in patients with diabetic disease. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 1999;13:278-7.
21. Andree C, Swain WF, Page CP, Macklin MD, Slama J, Hatzis D, Eriksson E. In vivo transfer and expression of a human epidermal growth factor gene accelerates wound repair. Proc Natl Acad Sci USA 1994;91:12188-92.
22. Margolis DJ, Crombleholme T, Herlyn M, Clinical protocol. Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Rep Reg 2000;8:480-93.
23. Favoni RE, Cupis AD. The role of polypeptide growth factors in human carcinomas: New targets for a novel pharmacological approach. Pharmacol Rev 2000;52:179-205.
24. Nguyen M, Watanabe H, Budson AW, Richie JP, Folkman J. Elevated levels of angiogenic peptides, basic fibroblast growth factor, in urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1993;86:356-61.
25. Li VW, Folkerth RD, Watanabe H, Yu C, Rupnick M, Barnes P, Scott RM, Black PM, Sallan SE, Folkman J. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumors. Lancet 1994;344:82-6.
26. Wang S, Zhou L, Ma Z, Yi S. Experimental observation on ADRs of recombinant human epidermal growth factor (rhEGF) in healthy and burned volunteers. Chin New Drugs J 2000;9:34-6.
27. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet 2003;361:1545-51.
28. Schultz GS, Sibbald RG, Falanga V, Ayello EA, Dowseit C, Harding K, Romanelli M, Stacey M, Teot L, Vanscheidt W. Wound bed preparation: a systematic approach to wound management. Wound Rep Reg 2003;11:S1-S28.
29. Li J, Fu X, Sun X, Sun T, Sheng Z. The interaction between epidermal growth factor and matrix metalloproteinase's induces the development of sweat glands in human fetal skin. J Surg Res 2002;106:258-63.
30. Slack JMW. Stem cells in epithelial tissues. Science 2000;287:1431-3.
31. Fiona M, Watt FM, Brigid LM. Out of eden: stem cell and their niches. Science 2000;287:1427-30.
32. Blecher SR, Kapalanga J, Lalonde D. Induction of sweat glands by epidermal growth factor in murine X-linked anhidrotic ectodermal dysphasia. Nature (London) 1990;345:542-4.
33. Jones PH, Harper S, Watt FM. Stem cell patterning and fate in human epidermis. Cell 1995;80:83-93.
34. Tursad K, Troy TC. Epidermal cell lineage. Biochem Cell Biol 1998;76:889-98.
35. Streuli C. Extracellular matrix remodeling and cellular differentiation. Curr Opin Cell Biol 1999;11:634-40.
36. Schwartz MA, Baron V. Interactions between mitogenic stimuli, or a thousand and one connections. Curr Opin Cell Biol 1999;11:197-202.
37. Brivanlou AH, Gage FH, Jaenisch R, Jessell T, Melton D, Rossant J. Setting standards for human embryonic stem cells. Science 2003;300:913-6.
38. Robson MC, Phillips LG, Thomason A, Robson L, Pierce G. Platelet derived growth factor-BB for the treatment of chronic pressure ulcers. Lancet 1992;339:23-5.
39. Robson MC, Phillips LG, Thomason A, Altrock BW, Pence PC, Heggers JP, Johnston AF, McHugh TP, Anthony MS, Robson LE. Recombinant human platelet-derived growth factor-BB for the treatment of pressure ulcers. Ann Plast Surg 1992;129:193-201.
40. Mandracchia VJ, Sanders SM, Frerichs JA. The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers. A retrospective analysis. Clin Podiatr Med Surg 2001;18:189-209.
41. Robson MC, Mustoe TA, Hunt TK. The future of recombinant growth factors in the wound healing. Am J Surg 1998;176:80S-82S.
42. Bianchi L, Ginebri A, Hagman JH, Francesconi F, Carboni I, Chimenti S. Local treatment of chronic cutaneous leg ulcers with recombinant human granulocyte-macrophage colony-stimulating factor. J Eur Acad Dermatol Venereol 2002;16:595-8.
43. Hirshberg J, Coleman J, Marchant B, Rees RS. TGF-beta3 in the treatment of pressure ulcers: a preliminary report. Adv Skin Wound Care 2001;14:91-5.
44. Pierce GF, Tarpley JE, Allman RM, Goode PS, Serdar CM, Morris B, Mustoe TA, Vande Berg J. Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB. Am J Pathol 1994;145:1399-410.
45. Wieman TJ. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. Am J Surg 1998;176 (2A Suppl.): 74S-79S.
46. Rees RS, Robson MC, Smiell JM, Perry BH. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study. Wound Rep Reg 1999;7:141-7.
47. Klijn JGM, Berns PMJ, Schmitz PM, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer. A review on 5232 patients. Endocr Rev 1992;13:3-17.
48. Ellerbroek SM, Hudson LG, Stack MS. Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer 1998;78:331-7.
49. Di Blasio AM, Cremonesi L, Vigano P, Ferrari M, Gospodarowicz D, Vignali M, Jaffe RB. Basic fibroblast growth factor and its receptor messenger ribonuclcic acids are expressed in human ovarian epithelial neoplasm. Am J Obstet Gynecol 1993;169:1517-23.
50. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 1998;44:705-23.
51. Rasmussen AA, Cullen KJ. Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res Tread 1998;47:219-33.
52. Lambert S, Vivario J, Boniver J, Gol-Winkler R. Abnormal expression and structural modification of the insulin-like growth factor-II gene in human colorectal cancer. Int J Cancer 1990;46:405-10.
53. Kawai T, Hiroi S, Torikata C. Expression in lung carcinomas of platelet-derived growth factor and its receptor. Lab Invest 1997;77:431-6.
54. Dabrow MB, Francesco MR, Mcbrearty FX, Caradonna S. The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 1998;71:29-37.